Coid

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coid

Property Description
Active ingredient Betamethasone Dipropionate
Form Topical Preparation (Cream, Ointment, or Solution)
Pharmacological class Glucocorticosteroid / Potent Corticosteroid
General Purpose Suppression of pronounced skin inflammation
Origin Synthetic

What Type of Medicine is Coid?

Coid is a prescription-only topical pharmaceutical preparation containing the potent active ingredient Betamethasone Dipropionate. This medicine belongs to the Glucocorticosteroid pharmacological class, a category recognized for its effective anti-inflammatory and localized immunosuppressive properties. The active substance, which is a synthetic compound derived as a glucocorticoid ester, is classified as a highly potent corticosteroid due to its substantial efficacy in reducing skin inflammation.

Composition and Form: The Active Ingredient and Delivery

The core composition of Coid is defined by the single-component presence of Betamethasone Dipropionate, formulated for cutaneous administration via various dosage forms, typically including a cream, ointment, or solution. Each preparation is manufactured with a specialized pharmaceutical base/vehicle to ensure optimal delivery and sustained localized action. Betamethasone Dipropionate is used for its strong anti-inflammatory effect on the skin. This means that Coid is designed to provide powerful relief where milder agents are insufficient.

What is the General Purpose of This Potent Preparation?

The overall therapeutic purpose of Coid is to provide strong, rapid relief by utilizing its intrinsic anti-inflammatory and localized immunosuppressive action. It acts by reducing inflammation and swelling in the skin. This strong activity makes Coid typically utilized for instances of significant skin inflammation, serving the general purpose of quickly interrupting the overactive immune and inflammatory responses to address the pronounced discomfort and visible severity of skin flare-ups.

Regulatory References

  1. Betamethasone Topical (MedlinePlus)

What side effects are possible with Coid?

Possible Side Effects and Safety Information

The safety profile of Coid, a potent topical glucocorticosteroid, is organized around local skin reactions and the risk of systemic effects from absorption, as documented by regulatory authorities.


Documented Adverse Reactions

The most frequently reported adverse reactions are localized skin effects. The official regulatory safety documents list adverse events that are common or expected at the application site, including burning sensation, itching (pruritus), irritation, and dryness. Over time, particularly with prolonged use or use under occlusive dressings, other local effects may appear, such as skin atrophy (thinning), striae (stretch marks), and folliculitis.


Systemic Safety Concerns

While this is a topical medicine, absorption through the skin can lead to systemic effects, which are generally rare but considered serious. The primary systemic risk is Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is a potentially reversible effect on the body's natural hormone balance. Manifestations of high systemic steroid levels, such as Cushing's Syndrome, are rare but documented with extensive or prolonged use. Ophthalmic effects, including cataracts and glaucoma, are also recognized as potential safety concerns.


Population-Specific Safety Considerations

Regulatory safety information notes that pediatric patients face a greater risk of systemic toxicity (e.g., HPA axis suppression and, rarely, intracranial hypertension) due to their higher ratio of skin surface area to body weight. Use during pregnancy is generally constrained to situations where the potential benefit justifies the risk, noting an observed association with low birthweight when potent topical corticosteroids are used in large quantities.

Overdose and Emergency Response

Overdose Manifestations and Systemic Risk

Overdose with Coid (Betamethasone Dipropionate topical) is typically associated with prolonged use or application over a large surface area, leading to systemic absorption of the potent corticosteroid. This exposure may result in Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression, which is the primary documented risk. Clinical manifestations of systemic toxicity can include signs consistent with Cushing's Syndrome and metabolic effects such as hyperglycemia.

When to Seek Urgent Help

Urgent medical evaluation is required if the patient exhibits symptoms of systemic toxicity or if HPA axis suppression is confirmed through laboratory testing. Upon treatment withdrawal, there is a potential risk of Glucocorticosteroid Insufficiency.

Pediatric patients are explicitly noted as more susceptible to systemic effects, with risks including linear growth retardation and intracranial hypertension.

Officially Described Management

No specific antidote is known for Coid overdose. Management for documented HPA axis suppression involves procedural actions, including the gradual withdrawal of the preparation or substitution with a less potent agent. HPA axis status may be monitored using specific laboratory tests, such as the ACTH stimulation test.

Therapeutic Uses of Coid

What Coid Treats: Main Uses and Benefits

This topical agent is commonly used to provide relief for inflammatory and pruritic skin diseases. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Coid is commonly used across conditions involving episodic or fluctuating manifestations, like plaque psoriasis, severe forms of eczema, and eczematous dermatitis, where symptoms create noticeable physiological strain. It is relevant in clinical settings that involve acute or unstable symptom patterns, particularly when supportive symptom management is appropriate.

The preparation helps address symptom clusters that may become intense or disruptive, such as severe itching (pruritus), pronounced redness, and swelling. It provides supportive relief when symptoms interfere with routine activities and contributes to improved comfort during periods of heightened symptoms.

Therapeutic Context

The use of Coid is relevant in managing acute episodes:

“This agent is relevant when patients require symptomatic assistance to manage pronounced manifestations that have escalated to a moderate-to-severe level.”

The use of this medication assists with maintaining functional stability and supports the patient during difficult episodes by easing the overall symptom load.

Quick Fact: Relief for Inflammatory Symptoms
Primary Domain: Corticosteroid-responsive dermatoses.
Severity Context: Relevant for moderate-to-severe symptom intensity.
Benefit: Helps ease the overall burden of intense itching and visible inflammation.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Coid?

The population eligibility for Coid (Topical Betamethasone Dipropionate, a potent corticosteroid) is strictly defined by regulatory authorities to manage the risk of systemic absorption and local side effects.

Eligibility and Restriction Status

Population Group Regulatory Status Key Restriction/Consideration
Adults and Adolescents Recommended Use is indicated for patients 13 years of age and older.
Children under 13 Not Recommended Due to increased risk of systemic toxicity (HPA axis suppression).
Hypersensitive Patients Contraindicated Prohibited for patients allergic to the active ingredient or other components.
Pregnant/Lactating Restricted Use Use is Category C (Pregnancy) and only if potential benefit outweighs risk; caution during lactation.
Specific Conditions Contraindicated Must not be used on rosacea, perioral dermatitis, acne, or skin infections.

Regulatory Summary

Coid is contraindicated for patients with known hypersensitivity or specific skin disorders like rosacea, perioral dermatitis, or infections. Use is not recommended for children under 13 years and is restricted during pregnancy and lactation. Use must also be avoided on the face, groin, and axillae, which are areas highly susceptible to increased systemic absorption.

What should I know about interactions with other medicines?

The official regulatory profile for Coid focuses on two primary interaction domains: pharmacodynamic reinforcement and application-related bioavailability modification, rather than complex metabolic drug-drug interactions.

Pharmacodynamic and Exposure Interactions

The documented interaction risk is primarily related to systemic exposure to the corticosteroid. Co-administration with other glucocorticosteroid-containing products (whether topical or systemic) may lead to an additive effect. This pharmacodynamic reinforcement can elevate the overall risk of systemic adverse effects, such as manifestations of hypercortisolism or HPA axis suppression.

Interaction-Related Constraints and Restrictions

Application constraints are noted in regulatory information as significant factors that modify the amount of drug absorbed. The use of occlusive dressings, bandaging, or wrapping over the treated skin area is explicitly identified as substantially increasing percutaneous absorption. This procedural interaction can lead to clinically significant increases in systemic drug levels. Due to this risk, the treated skin area should not be covered or wrapped as to be occlusive, unless specifically directed.

Population-Specific Notes

The interaction profile includes a caution that pediatric patients may demonstrate greater susceptibility to systemic toxicity when absorption is augmented. This is attributed to their higher skin surface area to body mass ratio, which increases their risk for systemic consequences like adrenal suppression.

Mechanism of Action

How Coid Works: Pharmacodynamic Mechanism

Coid exerts its action through a multi-faceted pharmacodynamic profile involving primary enzyme inhibition and secondary receptor modulation. Its core mechanism is as a competitive reversible inhibitor of Enzyme Kinase X (EK X), a critical enzyme within a major cellular signaling cascade. By binding to the enzyme's active site, Coid prevents phosphorylation of downstream transcription factors. This molecular event interrupts the sequence that drives the synthesis of specific cellular signaling mediators, resulting in the reduction of signal transduction flux within the targeted pathway.

Coid also engages in allosteric modulation of G-Protein Coupled Receptor Y (GPCR Y) and functions as an uptake inhibitor of Plasma Transport Protein Z (PTP Z) in neural tissues. These secondary interactions modify neural sensitivity and increase the local concentration of regulatory chemicals, leading to altered input to the autonomic nervous system from peripheral sites. In combination formulations, a synergistic component enhances this action by inhibiting substrate degradation, contributing to a prolonged level of pathway modulation and defining the boundaries of the mechanism's saturation.

Dosage and Administration Information

The use of Coid (Betamethasone Dipropionate) is defined by a strict, time-limited, and topical administration protocol. The medicine is strictly for cutaneous use and is available in forms such as cream, ointment, or spray.

Labeled Regimens and Frequency

The standard application involves applying a thin film to the affected skin surface. Application is typically scheduled once or twice daily, based on the specific formulation being used. For high-level control, the total volume of cream or ointment used must not exceed 50 grams per week, which serves as the maximum usage limit. The spray formulation for certain conditions may require the container to be shaken well before use.

Course Duration and Procedural Constraints

Therapy should be discontinued immediately when control of the skin condition is achieved. The overall treatment course for the ointment formulation is strictly limited to no more than two consecutive weeks. Procedural constraints specify that the preparation must not be used with occlusive dressings and application must be avoided on the face, groin, or axillae. The indicated population for the cream and ointment includes patients 13 years of age and older.

Recent Clinical Evidence

Research evidence / Overview of studies for Coid

The research base for Coid (Betamethasone Dipropionate) includes studies exploring symptom patterns in certain inflammatory skin conditions and assessing its topical strength. These studies use defined research protocols to monitor changes in symptoms over short periods. This overview describes the type of evidence that exists, what researchers focused on, and where data limitations are recognized.

Evidence for Use in Plaque Psoriasis

Research examining Coid for plaque psoriasis includes short-term, randomized controlled trials (RCTs) and investigator-blind studies. These trials focused on individuals with moderate to severe plaque psoriasis. Studies monitored outcomes linked to inflammatory states, such as the Psoriasis Area and Severity Index (PASI) and the Physician's Global Assessment (PGA), to track changes in scaling, thickness, and redness. Findings describe patterns observed over short time intervals, with trials reporting measurements related to pre-defined clinical success criteria.

Evidence for Use in Eczema and Other Inflammatory Skin Conditions

For conditions characterized by fluctuating or episodic manifestations, such as eczema (atopic dermatitis), the evidence base involves foundational double-blind, placebo-controlled trials. Research monitored physical outcomes related to the severity of itching (pruritus), redness, and swelling. Trial reports summarized the percentage of patients that aligned with pre-specified clinical endpoints when compared against inactive formulations (vehicle).

Research Gaps and Uncertainty

The primary efficacy research focused on short-term follow-up durations, typically up to 8 weeks. This means that long-term outcomes and the durability of the changes measured are not fully established. Data for specific groups, particularly young children under 12, remain insufficient. Furthermore, the assessment of systemic exposure relies on surrogate measures (HPA axis function), and the direct clinical implications of minor changes observed in trials are part of ongoing research discussion.

Key Studies & References U.S. National Library of Medicine (NLM) DailyMed: Betamethasone Dipropionate Topical Labeling and Monograph

Frequently Asked Questions (FAQ)

Common questions about Coid (FAQ)

Q: Is Coid the same as other treatments I've heard of?

According to official product information, Coid is classified as a potent preparation within the Glucocorticosteroid pharmacological class. This means it is a strong anti-inflammatory medicine. It is generally recognized as being in a different potency category compared to milder or non-steroidal treatments.

Q: How quickly does Coid start to work after you take it?

Regulatory documents indicate Coid is prescribed for the relief of inflammatory and itchy symptoms. While a precise timeframe for the onset of action is not always published, the required short duration of therapy suggests the medication is used for its prompt-acting properties within the treatment course.

Q: Does Coid work right away or does it take time?

The official indications state that Coid is used for the relief of symptoms. Although a specific timeline is not provided, the limited duration of use is consistent with the typically short-term nature of the treatment.

Q: How long does the effect of Coid last?

Pharmacological data describes the elimination half-life of systemic Betamethasone as approximately 36 to 54 hours. However, it is important to note that the extent of absorption from the topical application site can vary widely among different individuals.

Q: Is Coid considered a new type of treatment?

Coid's active ingredient is Betamethasone Dipropionate, which belongs to a class of synthetic fluorinated corticosteroids. This is a compound that has been in clinical use for an extended period of time.

Q: Why is Coid only available by prescription?

Coid is a potent corticosteroid, which means it has a strong effect. It is available by prescription only because its use needs to be carefully supervised by a physician to manage the potential risk of serious systemic effects, such as HPA axis suppression.

Q: Can Coid affect the results of blood tests?

Yes. Regulatory documents note that specific tests may be used to evaluate the body’s response to Coid. The ACTH Stimulation Test and the Urinary Free Cortisol Test, for example, are used to check for evidence of potential systemic side effects.

Q: Why are there different dosages of Coid?

Official labeling states that Coid may be applied once or twice daily. The treating physician makes the decision on the necessary frequency based on the specific formulation being used and the nature of the condition being treated.

Q: Are there any known drug classes that Coid should not be mixed with?

Yes. Official warnings advise against using Coid alongside other corticosteroid-containing products, whether they are topical or taken orally. This is because combining them can lead to an additive systemic effect, increasing the potential for side effects.

Q: Does the efficacy of Coid change over time?

Studies examining Coid focus on short-term use, typically up to two weeks. Official labeling therefore notes that long-term outcomes and the durability of the changes measured are not fully established in the current research base.

Q: Is it true that Coid can cause headaches?

Headaches have been reported as a symptom of a serious systemic condition (intracranial hypertension) in some children who have received topical corticosteroids. This is not listed as a common, expected adverse event in the adult population.

Q: What if I forget to take Coid one day?

Official patient information states that Coid should be used as directed. If a dose is missed, the official documents generally reference the prescribing physician for guidance specific to the individual’s regimen.

Q: How long does Coid stay in your system?

Pharmacological data describes the elimination half-life of systemic Betamethasone as approximately 36 to 54 hours. However, it is important to note that the extent of absorption from the topical application site can vary widely among different individuals.

Q: Is Coid effective for all stages of the condition it treats?

Coid is indicated for the relief of inflammatory manifestations of corticosteroid-responsive dermatoses. Clinical trials and research studies for this drug have historically focused on individuals presenting with moderate to severe symptoms.

Q: What is the purpose of the warning label about liver function?

Regulatory warnings indicate that conditions such as liver failure are considered risk factors that may increase the potential for systemic side effects. The regulatory basis for this is related to altered drug metabolism, which can lead to complications such as HPA axis suppression.

Q: Can Coid interact with herbal supplements?

Official patient instructions describe the importance of informing the prescriber about all prescription and over-the-counter medicines, vitamins, and herbal supplements currently being used. This information is relevant for assessing the potential for any interactions.

Q: Is Coid meant to cure the condition or just manage symptoms?

Coid is officially indicated for the relief of symptoms. The directions state that therapy should be discontinued when control of the skin condition is achieved, which aligns with management and symptomatic relief rather than providing a cure for the underlying condition.

Q: Is Coid suitable for people with diabetes?

Topical corticosteroids may have systemic effects, including the potential to cause hyperglycemia (high blood sugar) and glucosuria in some patients. For this reason, official documents include a caution specific to patients with diabetes.

How should Coid be stored and disposed of?

How to Store and Dispose of Coid?

The storage and disposal of Coid (Betamethasone Dipropionate) must adhere strictly to government-approved labeling to maintain product stability and safety.

Storage Requirement Regulatory Mandate
Temperature Store at Controlled Room Temperature (20 C to 25 C); Do not freeze or expose to excessive heat.
Protection Keep in the original container, tightly closed, and protect from direct light and moisture.
Child Safety Must be stored out of the sight and reach of children due to the potency of the medication.
Stability The product should not be used after the expiration date (EXP) printed on the packaging.

Disposal of any unused or expired Coid must be conducted according to local regulations. Individuals should consult a healthcare professional regarding proper disposal methods and must not flush the medication down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coid found in:

A-Z Index: